• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclo Therapeutics Inc (NQ: CYTH )

    0.7216 -0.0264 (-3.53%)
    Streaming Delayed Price Updated: 3:37 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cyclo Therapeutics Inc

    < Previous 1 2 3 4 5 6 Next >
    Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
    Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
    From Pacira BioSciences
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
    From Cyclo Therapeutics
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    This Hershey Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
    Via Benzinga
    CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results
    Via Benzinga
    Gold Down Over 1%; US Initial Jobless Claims Increase
    Via Benzinga
    CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
    From Rafael Holdings, Inc.; Cyclo Therapeutics
    Via GlobeNewswire
    CYTH Stock Earnings: Cyclo Therapeutics Misses EPS, Misses Revenue for Q2 2024
    CYTH stock results show that Cyclo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
    Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q1 2024
    Cyclo Therapeutics just reported results for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    CYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023
    Cyclo Therapeutics just reported results for the fourth quarter of 2023. 
    Via InvestorPlace
    Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.